Should I buy or sell Verastem stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VSTM shares. View VSTM analyst ratings or view top-rated stocks .

What is Verastem's stock price target for 2024?

7 Wall Street research analysts have issued 1 year price objectives for Verastem's stock. Their VSTM share price targets range from $21.00 to $36.00. On average, they predict the company's share price to reach $29.71 in the next year. This suggests a possible upside of 342.8% from the stock's current price. View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts .

How have VSTM shares performed in 2023?

Verastem's stock was trading at $4.83 at the beginning of 2023. Since then, VSTM stock has increased by 38.9% and is now trading at $6.71. View the best growth stocks for 2023 here .

When is Verastem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024. View our VSTM earnings forecast .

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) announced its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.17.

When did Verastem's stock split?

Shares of Verastem reverse split before market open on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com . Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD) , Micron Technology (MU) , Novavax (NVAX) , Inovio Pharmaceuticals (INO) , Gilead Sciences (gild) , Sorrento Therapeutics (SRNE) , SCYNEXIS (SCYX) , TG Therapeutics (TGTX) , Amarin (AMRN) and Viking Therapeutics (VKTX) .

Who are Verastem's major shareholders?

Verastem's stock is owned by a number of institutional and retail investors. Top institutional investors include Adage Capital Partners GP L.L.C. (5.14%), Acuta Capital Partners LLC (0.91%), Vontobel Holding Ltd. (0.81%), Sectoral Asset Management Inc. (0.80%), Northern Trust Corp (0.18%) and Royal Bank of Canada (0.17%). Insiders that own company stock include Brian M Stuglik , Dan Paterson , Daniel Calkins, Robert E Gagnon and Timothy J Barberich. View institutional ownership trends .

How do I buy shares of Verastem?

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Verastem Stock Price, News & Analysis (NASDAQ:VSTM)

$6.78

+0.38 (+5.94%)

(As of 03:15 PM ET)

Compare

Today's Range: $6.45
▼
$6.81
50-Day Range: $6.05
▼
$9.70
52-Week Range: $3.87
▼
$15.18

Volume: 69,448 shs
Average Volume: 163,105 shs
Market Capitalization: $171.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.71

Verastem MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 342.8% Upside
$29.71 Price Target
Short Interest: Healthy
2.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$7,565 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.67) to ($3.04) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

285th out of 949 stocks

Pharmaceutical Preparations Industry

121st out of 441 stocks

3.5

Analyst's Opinion

Consensus Rating
Verastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.71, Verastem has a forecasted upside of 342.8% from its current price of $6.71.
Amount of Analyst Coverage
Verastem has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.52% of the float of Verastem has been sold short.
Short Interest Ratio / Days to Cover
Verastem has a short interest ratio ("days to cover") of 6.
Change versus previous month
Short interest in Verastem has recently decreased by 15.01%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Verastem does not currently pay a dividend.
Dividend Growth
Verastem does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VSTM.

2.2

News and Social Media Coverage

News Sentiment
Verastem has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Verastem this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for VSTM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,565.00 in company stock.
Percentage Held by Insiders
Only 2.90% of the stock of Verastem is held by insiders.
Percentage Held by Institutions
75.25% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Verastem are expected to grow in the coming year, from ($3.67) to ($3.04) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verastem is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verastem is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verastem has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Verastem Stock (NASDAQ:VSTM)

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of avutometinib and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

VSTM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VSTM Stock News Headlines

November 23, 2023 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Rating Reiterated by BTIG Research

November 22, 2023 | finance.yahoo.com

All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 22, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Bluebird Bio (BLUE) and Verastem (VSTM)

November 15, 2023 | markets.businessinsider.com

Where Verastem Stands With Analysts

November 13, 2023 | finance.yahoo.com

New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

November 12, 2023 | seekingalpha.com

Verastem: Potential Accelerated Approval Filing In H1 2024

November 11, 2023 | msn.com

Verastem files $300M mixed securities shelf

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 10, 2023 | markets.businessinsider.com

Positive Outlook for Verastem: Accelerated Filing Plans, Financial Stability, and Upcoming Clinical Trials Underpin Buy Rating

November 8, 2023 | finance.yahoo.com

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 8, 2023 | markets.businessinsider.com

Verastem: Promising Phase 2 Results and Upcoming Phase 3 Study Bolsters Buy Rating

November 7, 2023 | finance.yahoo.com

First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer

November 6, 2023 | markets.businessinsider.com

Verastem Reports Positive Data Of Avutometinib & Defactinib In Low-Grade Serous Ovarian Cancer

November 6, 2023 | finance.yahoo.com

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

October 28, 2023 | markets.businessinsider.com

Verastem’s Strategic Executive Appointments and Potential FDA Approval Reinforce Buy Rating

October 27, 2023 | benzinga.com

Verastem Chief Financial Officer Awarded $162K Worth of Stock Options

October 26, 2023 | finance.yahoo.com

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

October 25, 2023 | finance.yahoo.com

Verastem Inc (2VS.BE)

October 25, 2023 | money.usnews.com

Verastem Inc

October 17, 2023 | markets.businessinsider.com

Promising Potential for Verastem’s Stock with RAMP 203 Results: A Comprehensive Analysis and Buy Recommendation

October 14, 2023 | finance.yahoo.com

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer

September 30, 2023 | nasdaq.com

B. Riley Securities Reiterates Verastem (VSTM) Buy Recommendation

September 28, 2023 | finance.yahoo.com

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

September 27, 2023 | markets.businessinsider.com

Analyst Ratings for Verastem

September 3, 2023 | msn.com

Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal

August 28, 2023 | msn.com

Verastem, China's GenFleet to collaborate on RAS pathway-driven cancer drugs

See More Headlines

Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/12/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:VSTM
CUSIP: 92337C10
CIK: 1526119
Web: www.verastem.com
Phone: (781) 292-4200
Fax: N/A
Employees: 57
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $29.71
High Stock Price Target: $36.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +364.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.0408)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-73,810,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -115.85%
Return on Assets: -52.62%

Debt

Debt-to-Equity Ratio: 0.48
Current Ratio: 7.33
Quick Ratio: 7.33

Sales & Book Value

Annual Sales: $2.60 million
Price / Sales: 62.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.29 per share
Price / Book: 1.95

Miscellaneous

Outstanding Shares: 25,270,000
Free Float: 24,534,000
Market Cap: $161.73 million
Optionable: Optionable
Beta: 0.56

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Daniel W. Paterson (Age 62)
President, CEO & Director
Comp: $697.98k
Mr. Daniel Calkins (Age 36)
CFO, Head of Investor Relations, Principal Accounting Officer & Financial Officer
Comp: $310.67k
Mr. Richard H. Aldrich M.B.A. (Age 69)
Founder and Consultant
Comp: $38.39k
Dr. Robert A. Weinberg Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Dr. Piyush B. Gupta Ph.D.
Co-Founder
Dr. Michelle Dipp M.D. (Age 47)
Ph.D., Co-Founder
Mr. Robert Pintar M.B.A.
Senior Vice President of Technical Operations
Dr. Jonathan Pachter Ph.D. (Age 65)
Chief Scientific Officer
Comp: $238.18k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VSTM Stock Analysis - Frequently Asked Questions

Should I buy or sell Verastem stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VSTM shares.
View VSTM analyst ratings or view top-rated stocks.
What is Verastem's stock price target for 2024?: 7 Wall Street research analysts have issued 1 year price objectives for Verastem's stock. Their VSTM share price targets range from $21.00 to $36.00. On average, they predict the company's share price to reach $29.71 in the next year. This suggests a possible upside of 342.8% from the stock's current price.
View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts.
How have VSTM shares performed in 2023?: Verastem's stock was trading at $4.83 at the beginning of 2023. Since then, VSTM stock has increased by 38.9% and is now trading at $6.71.
View the best growth stocks for 2023 here.
When is Verastem's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our VSTM earnings forecast.
How were Verastem's earnings last quarter?: Verastem, Inc. (NASDAQ:VSTM) announced its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.17.
When did Verastem's stock split?: Shares of Verastem reverse split before market open on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Robert Forrester's approval rating as Verastem's CEO?: 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Verastem own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).
Who are Verastem's major shareholders?: Verastem's stock is owned by a number of institutional and retail investors. Top institutional investors include Adage Capital Partners GP L.L.C. (5.14%), Acuta Capital Partners LLC (0.91%), Vontobel Holding Ltd. (0.81%), Sectoral Asset Management Inc. (0.80%), Northern Trust Corp (0.18%) and Royal Bank of Canada (0.17%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins, Robert E Gagnon and Timothy J Barberich.
View institutional ownership trends.
How do I buy shares of Verastem?: Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:VSTM) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial